Future challenges and treatment of Staphylococcus aureus bacteremia with emphasis on MRSA

Future Microbiology

Volumn 6, Issue 1, 2011, Pages 43-56

  Rasmussen, Rasmus V ^a   Fowler Jr, Vance G ^b   Skov, Robert ^c   Bruun, Niels E ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c STATENS SERUM INSTITUT   (Denmark)

Author keywords

bacteremia; epidemiology; infective endocarditis; MRSA; Staphylococcus aureus; treatment

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM; CEFTAROLINE; CEFTOBIPROLE; DALBAVANCIN; DAPTOMYCIN; LINEZOLID; ORITAVENCIN; PENICILLIN G; RIFAMPICIN; TEICOPLANIN; TELAVANCIN; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ABDOMINAL INFECTION; BACTERIAL ENDOCARDITIS; BACTERIAL GENETICS; BACTERICIDAL ACTIVITY; BLOODSTREAM INFECTION; BONE MARROW SUPPRESSION; COMMUNITY ACQUIRED PNEUMONIA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG HALF LIFE; DRUG TOLERABILITY; HEADACHE; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INFECTIOUS ARTHRITIS; LACTIC ACIDOSIS; LIVER TOXICITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; OPTIC NERVE DISEASE; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SEROTONIN SYNDROME; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TASTE DISORDER; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; UNSPECIFIED SIDE EFFECT; VOMITING;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTEREMIA; CROSS INFECTION; ENDOCARDITIS; HUMANS; LIVESTOCK; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS;

EID: 78650477195     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.10.155     Document Type: Review

References (148)

1. Biedenbach DJ, Moet GJ, Jones RN: Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn. Microbiol. Infect. Dis. 50(1), 59-69 (2004).
2. Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348(16), 1546-1554 (2003).
3. Lyytikainen O, Ruotsalainen E, Jarvinen A, Valtonen V, Ruutu P: Trends and outcome of nosocomial and community-acquired bloodstream infections due to Staphylococcus aureus in Finland, 1995-2001. Eur. J. Clin. Microbiol. Infect. Dis. 24(6), 399-404 (2005).
4. Benfield T, Espersen F, Frimodt-Moller N et al.: Increasing incidence but decreasing in-hospital mortality of adult Staphylococcus aureus bacteraemia between 1981 and 2000. Clin. Microbiol. Infect. 13(3), 257-263 (2007).
5. Fowler VG Jr, Olsen MK, Corey GR et al.: Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch. Intern. Med. 163(17), 2066-2072 (2003).
6. Rieg S, Peyerl-Hoffmann G, de With K et al.: Mortality of S. aureus bacteremia and infectious diseases specialist consultation - a study of 521 patients in Germany. J. Infect. 59(4), 232-239 (2009).
7. Cosgrove SE, Sakoulas G, Perencevich EN et al.: Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin. Infect. Dis. 36(1), 53-59 (2003).
8. Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML: Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin. Microbiol. Rev. 23(1), 99-139 (2010).
9. von EC, Becker K, Machka K, Stammer H, Peters G: Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N. Engl. J. Med. 344(1), 11-16 (2001). (Pubitemid 32064839)
10. Wertheim HF, Vos MC, Ott A et al.: Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet 364(9435), 703-705 (2004).
11. Laupland KB, Ross T, Gregson DB: Staphylococcus aureus bloodstream infections: risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000-2006. J. Infect. Dis. 198(3), 336-343 (2008).
12. Frimodt-Moller N, Espersen F, Skinhoj P, Rosdahl VT: Epidemiology of Staphylococcus aureus bacteremia in Denmark from 1957 to 1990. Clin. Microbiol. Infect. 3(3), 297-305 (1997).
13. Banerjee SN, Emori TG, Culver DH et al.: Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am. J. Med. 91(3B), 86S-89S (1991).
14. Chang FY, MacDonald BB, Peacock JE Jr et al.: A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (Baltimore) 82(5), 322-332 (2003).
15. Hill EE, Vanderschueren S, Verhaegen J et al.: Risk factors for infective endocarditis and outcome of patients with Staphylococcus aureus bacteremia. Mayo Clin. Proc. 82(10), 1165-1169 (2007).
16. Jensen AG, Wachmann CH, Poulsen KB et al.: Risk factors for hospital-acquired Staphylococcus aureus bacteremia. Arch. Intern. Med. 159(13), 1437-1444 (1999).
17. Benito N, Miro JM, de Lazzari E et al.: Health care-associated native valve endocarditis: importance of non-nosocomial acquisition. Ann. Intern. Med. 150(9), 586-594 (2009).
18. Styers D, Sheehan DJ, Hogan P, Sahm DF: Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann. Clin. Microbiol. Antimicrob. 5, 2 (2006).
19. Klevens RM, Morrison MA, Nadle J et al.: Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298(15), 1763-1771 (2007).
20. Lesens O, Hansmann Y, Brannigan E et al.: Healthcare-associated Staphylococcus aureus bacteremia and the risk for methicillin resistance: is the Centers for Disease Control and Prevention definition for community-acquired bacteremia still appropriate? Infect. Control Hosp. Epidemiol. 26(2), 204-209 (2005).
21. EARSS Management Team: European Antimicrobial Resistance Surveillance System Annual Report 2008. Bilthoven, The Netherlands (2008).
22. Kaiser AM, Haenen AJ, de Neeling AJ, Vandenbroucke-Grauls CM.: Prevalence of methicillin-resistant Staphylococcus aureus and risk factors for carriage in Dutch hospitals. Infect. Control Hosp. Epidemiol. 31(11), 1188-1190 (2010).
23. Moodley A, Nightingale EC, Stegger M et al.: High risk for nasal carriage of methicillin-resistant Staphylococcus aureus among Danish veterinary practitioners. Scand. J. Work Environ. Health 34(2), 151-157 (2008).
24. van Cleef BA, Verkade EJ, Wulf MW et al.: Prevalence of livestock-associated MRSA in communities with high pig-densities in The Netherlands. PLoS ONE 5(2), e9385 (2010).
25. Nickerson EK, Wuthiekanun V, Day NP, Chaowagul W, Peacock SJ.: Methicillin-resistant Staphylococcus aureus in rural Asia. Lancet Infect. Dis. 6(2), 70-71 (2006).
26. Nickerson EK, Hongsuwan M, Limmathurotsakul D et al.: Staphylococcus aureus bacteraemia in a tropical setting: patient outcome and impact of antibiotic resistance. PLoS ONE 4(1), e4308 (2009).
27. Nickerson EK, Wuthiekanun V, Wongsuvan G et al.: Factors predicting and reducing mortality in patients with invasive Staphylococcus aureus disease in a developing country. PLoS ONE 4(8), e6512 (2009).
28. Peacock SJ, Newton PN.: Public health impact of establishing the cause of bacterial infections in rural Asia. Trans. R Soc. Trop. Med. Hyg. 102(1), 5-6 (2008).
29. Daum RS.: Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N. Engl. J. Med. 357(4), 380-390 (2007).
30. Moran GJ, Krishnadasan A, Gorwitz RJ et al.: Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. 355(7), 666-674 (2006).
31. Groom AV, Wolsey DH, Naimi TS et al.: Community-acquired methicillin-resistant Staphylococcus aureus in a rural American Indian community. JAMA 286(10), 1201-1205 (2001).
32. Kazakova SV, Hageman JC, Matava M et al.: A clone of methicillin- resistant Staphylococcus aureus among professional football players. N. Engl. J. Med. 352(5), 468-475 (2005).
33. Pan ES, Diep BA, Carleton HA et al.: Increasing prevalence of methicillin-resistant Staphylococcus aureus infection in California jails. Clin. Infect. Dis. 37(10), 1384-1388 (2003).
34. Weber JT: Community-associated methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 41(Suppl. 4), S269-S272 (2005).
35. Zinderman CE, Conner B, Malakooti MA et al.: Community-acquired methicillin-resistant Staphylococcus aureus among military recruits. Emerg. Infect. Dis. 10(5), 941-944 (2004).
36. Diep BA, Chambers HF, Graber CJ et al.: Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann. Intern. Med. 148(4), 249-257 (2008).
37. Gorwitz RJ, Kruszon-Moran D, McAllister SK et al.: Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001-2004. J. Infect. Dis. 197(9), 1226-1234 (2008).
38. Naimi TS, LeDell KH, Como-Sabetti K et al.: Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 290(22), 2976-2984 (2003).
39. McDougal LK, Steward CD, Killgore GE et al.: Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J. Clin. Microbiol. 41(11), 5113-5120 (2003).
40. Tenover FC, McDougal LK, Goering RV et al.: Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States. J. Clin. Microbiol. 44(1), 108-118 (2006).
41. Liao CH, Chen SY, Huang YT, Hsueh PR: Outcome of patients with meticillin-resistant Staphylococcus aureus bacteraemia at an Emergency Department of a medical centre in Taiwan. Int. J. Antimicrob. Agents 32(4), 326-332 (2008).
42. Schramm GE, Johnson JA, Doherty JA, Micek ST, Kollef MH: Methicillin-resistant Staphylococcus aureus sterile-site infection: the importance of appropriate initial antimicrobial treatment. Crit. Care Med. 34(8), 2069-2074 (2006).
43. Miro JM, Anguera I, Cabell CH et al.: Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. Clin. Infect. Dis. 41(4), 507-514 (2005).
44. Rasmussen RV, Snygg-Martin U, Olaison L et al.: Major cerebral events in Staphylococcus aureus infective endocarditis: is anticoagulant therapy safe? Cardiology 114(4), 284-291 (2009).
45. Roder BL, Wandall DA, Espersen F et al.: Neurologic manifestations in Staphylococcus aureus endocarditis: a review of 260 bacteremic cases in nondrug addicts. Am. J. Med. 102(4), 379-386 (1997).
46. Fowler VG Jr, Miro JM, Hoen B et al.: Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 293(24), 3012-3021 (2005).
47. Darouiche RO: Device-associated infections: a macroproblem that starts with microadherence. Clin. Infect. Dis. 33(9), 1567-1572 (2001).
48. Voigt A, Shalaby A, Saba S: Rising rates of cardiac rhythm management device infections in the United States: 1996 through 2003. J. Am. Coll. Cardiol. 48(3), 590-591 (2006).
49. Chamis AL, Peterson GE, Cabell CH et al.: Staphylococcus aureus bacteremia in patients with permanent pacemakers or implantable cardioverter-defibrillators. Circulation 104(9), 1029-1033 (2001).
50. El-Ahdab F, Benjamin DK Jr, Wang A et al.: Risk of endocarditis among patients with prosthetic valves and Staphylococcus aureus bacteremia. Am. J. Med. 118(3), 225-229 (2005).
51. Sohail MR, Uslan DZ, Khan AH et al.: Management and outcome of permanent pacemaker and implantable cardioverter-defibrillator infections. J. Am. Coll. Cardiol. 49(18), 1851-1859 (2007).
52. Uslan DZ, Sohail MR, St Sauver JL et al.: Permanent pacemaker and implantable cardioverter defibrillator infection: a population-based study. Arch. Intern. Med. 167(7), 669-675 (2007).
53. Baddour LM, Epstein AE, Erickson CC et al.: Update on cardiovascular implantable electronic device infections and their management. a scientific statement from the American Heart Association. Circulation 121, 458-477 (2010).
54. Chu VH, Crosslin DR, Friedman JY et al.: Staphylococcus aureus bacteremia in patients with prosthetic devices: costs and outcomes. Am. J. Med. 118(12), 1416 (2005).
55. Habib G, Hoen B, Tornos P et al.: Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Eur. Heart J. 30(19), 2369-2413 (2009).
56. Wilson W, Taubert KA, Gewitz M et al.: Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 116(15), 1736-1754 (2007).
57. Abraham J, Mansour C, Veledar E, Khan B, Lerakis S: Staphylococcus aureus bacteremia and endocarditis: the Grady Memorial Hospital experience with methicillin-sensitive S. aureus and methicillin-resistant S. aureus bacteremia. Am. Heart J. 147(3), 536-539 (2004).
58. Fowler VG Jr, Li J, Corey GR et al.: Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients. J. Am. Coll. Cardiol. 30(4), 1072-1078 (1997).
59. Roder BL, Wandall DA, Frimodt-Moller N et al.: Clinical features of Staphylococcus aureus endocarditis: a 10-year experience in Denmark. Arch. Intern. Med. 159(5), 462-469 (1999).
60. Casella F, Rana B, Casazza G et al.: The potential impact of contemporary transthoracic echocardiography on the management of patients with native valve endocarditis: a comparison with transesophageal echocardiography. Echocardiography 26(8), 900-906 (2009).
61. Corey GR: Staphylococcus aureus bloodstream infections: definitions and treatment. Clin. Infect. Dis. 48(Suppl. 4), S254-S259 (2009).
62. Mermel LA, Allon M, Bouza E et al.: Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 49(1), 1-45 (2009).
63. van BA, Melles DC, Nouwen J et al.: Co-evolutionary aspects of human colonisation and infection by Staphylococcus aureus. Infect. Genet. Evol. 9(1), 32-47 (2009).
64. Melles DC, Gorkink RF, Boelens HA et al.: Natural population dynamics and expansion of pathogenic clones of Staphylococcus aureus. J. Clin. Invest. 114(12), 1732-1740 (2004).
65. Feil EJ, Cooper JE, Grundmann H et al.: How clonal is Staphylococcus aureus? J. Bacteriol. 185(11), 3307-3316 (2003).
66. Robinson DA, Enright MC: Multilocus sequence typing and the evolution of methicillin-resistant Staphylococcus aureus. Clin. Microbiol. Infect. 10(2), 92-97 (2004).
67. Melles DC, Tenover FC, Kuehnert MJ et al.: Overlapping population structures of nasal isolates of Staphylococcus aureus from healthy Dutch and American individuals. J. Clin. Microbiol. 46(1), 235-241 (2008).
68. Fowler VG Jr, Nelson CL, McIntyre LM et al.: Potential associations between hematogenous complications and bacterial genotype in Staphylococcus aureus infection. J. Infect. Dis. 196(5), 738-747 (2007).
69. Peacock SJ, Moore CE, Justice A et al.: Virulent combinations of adhesin and toxin genes in natural populations of Staphylococcus aureus. Infect. Immun. 70(9), 4987-4996 (2002).
70. Campbell SJ, Deshmukh HS, Nelson CL et al.: Genotypic characteristics of Staphylococcus aureus isolates from a multinational trial of complicated skin and skin structure infections. J. Clin. Microbiol. 46(2), 678-684 (2008).
71. Harris SR, Feil EJ, Holden MT et al.: Evolution of MRSA during hospital transmission and intercontinental spread. Science 327(5964), 469-474 (2010).
72. Patti JM, Allen BL, McGavin MJ, Hook M: MSCRAMM-mediated adherence of microorganisms to host tissues. Annu. Rev. Microbiol. 48, 585-617 (1994).
73. Miajlovic H, Loughman A, Brennan M, Cox D, Foster TJ: Both complement- and fibrinogen-dependent mechanisms contribute to platelet aggregation mediated by Staphylococcus aureus clumping factor B. Infect. Immun. 75(7), 3335-3343 (2007).
74. O'Brien L, Kerrigan SW, Kaw G et al.: Multiple mechanisms for the activation of human platelet aggregation by Staphylococcus aureus: roles for the clumping factors ClfA and ClfB, the serine-aspartate repeat protein SdrE and protein A. Mol. Microbiol. 44(4), 1033-1044 (2002).
75. Sinha B, Francois P, Que YA et al.: Heterologously expressed Staphylococcus aureus fibronectin-binding proteins are sufficient for invasion of host cells. Infect. Immun. 68(12), 6871-6878 (2000).
76. Edwards AM, Potts JR, Josefsson E, Massey RC: Staphylococcus aureus host cell invasion and virulence in sepsis is facilitated by the multiple repeats within FnBPA. PLoS Pathog. 6(6), e1000964 (2010).
77. Foster TJ: The Staphylococcus aureus 'superbug'. J. Clin. Invest. 114(12), 1693-1696 (2004).
78. Sabat A, Melles DC, Martirosian G et al.: Distribution of the serine-aspartate repeat protein-encoding sdr genes among nasal-carriage and invasive Staphylococcus aureus strains. J. Clin. Microbiol. 44(3), 1135-1138 (2006).
79. Trad S, Allignet J, Frangeul L et al.: DNA macroarray for identification and typing of Staphylococcus aureus isolates. J. Clin. Microbiol. 42(5), 2054-2064 (2004).
80. Xiong YQ, Fowler VG, Yeaman MR et al.: Phenotypic and genotypic characteristics of persistent methicillin-resistant Staphylococcus aureus bacteremia in vitro and in an experimental endocarditis model. J. Infect. Dis. 199(2), 201-208 (2009).
81. Lalani T, Federspiel JJ, Boucher HW et al.: Associations between the genotypes of Staphylococcus aureus bloodstream isolates and clinical characteristics and outcomes of bacteremic patients. J. Clin. Microbiol. 46(9), 2890-2896 (2008).
82. Croze M, Dauwalder O, Dumitrescu O et al.: Serum antibodies against Panton-Valentine leukocidin in a normal population and during Staphylococcus aureus infection. Clin. Microbiol. Infect. 15(2), 144-148 (2009).
83. Gillet Y, Issartel B, Vanhems P et al.: Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 359(9308), 753-759 (2002).
84. Jahamy H, Ganga R, Al RB et al.: Staphylococcus aureus skin/soft-tissue infections: the impact of SCCmec type and Panton-Valentine leukocidin. Scand. J. Infect. Dis. 40(8), 601-606 (2008).
85. Labandeira-Rey M, Couzon F, Boisset S et al.: Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science 315(5815), 1130-1133 (2007). (Pubitemid 46328024)
86. Bohach GA, Fast DJ, Nelson RD, Schlievert PM: Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses. Crit. Rev. Microbiol. 17(4), 251-272 (1990).
87. Murray RJ: Recognition and management of Staphylococcus aureus toxin-mediated disease. Intern. Med. J. 35(Suppl. 2), S106-S119 (2005).
88. Gould IM: Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus. Int. J. Antimicrob. Agents 31(Suppl. 2), 1-9 (2008).
89. Chang FY, Peacock JE Jr, Musher DM et al.: Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 82(5), 333-339 (2003).
90. Gentry CA, Rodvold KA, Novak RM, Hershow RC, Naderer OJ: Retrospective evaluation of therapies for Staphylococcus aureus endocarditis. Pharmacotherapy 17(5), 990-997 (1997).
91. Stryjewski ME, Szczech LA, Benjamin DK Jr et al.: Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin. Infect. Dis. 44(2), 190-196 (2007).
92. Lodise TP, Graves J, Evans A et al.: Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother. 52(9), 3315-3320 (2008).
93. Pea F, Viale P: Is the minimum inhibitory concentration of vancomycin an infallible predictor of the clinical outcome of Staphylococcus aureus bacteremia treated with vancomycin? Clin. Infect. Dis. 49(4), 642-643 (2009).
94. Price J, Atkinson S, Llewelyn M, Paul J: Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin. Clin. Infect. Dis. 48(7), 997-998 (2009).
95. Lalueza A, Chaves F, San JR et al.: Is high vancomycin minimum inhibitory concentration a good marker to predict the outcome of methicillin-resistant Staphylococcus aureus bacteremia? J. Infect. Dis. 201(2), 311-312 (2010).
96. Wikler MA, Cockerill FR 3rd, Craig WA et al.: Performance Standards for Antimicrobial Susceptibility Testing: Seventeenth International Supplement M100-S16. Clinical and Laboratory Standards Institute, PA, USA 26(3), (2006).
97. Appelbaum PC: Reduced glycopeptide susceptibility in methicillin- resistant Staphylococcus aureus (MRSA). Int. J. Antimicrob. Agents 30(5), 398-408 (2007).
98. de LA, Hidri N, Timsit JF et al.: Control and outcome of a large outbreak of colonization and infection with glycopeptide-intermediate Staphylococcus aureus in an intensive care unit. Clin. Infect. Dis. 42(2), 170-178 (2006).
99. Garnier F, Chainier D, Walsh T et al.: A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital. J. Antimicrob. Chemother. 57(1), 146-149 (2006).
100. Maor Y, Rahav G, Belausov N et al.: Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center. J. Clin. Microbiol. 45(5), 1511-1514 (2007).
101. Bae IG, Federspiel JJ, Miro JM et al.: Heterogeneous vancomycin- intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance. J. Infect. Dis. 200(9), 1355-1366 (2009).
102. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML: Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin. Infect. Dis. 38(3), 448-451 (2004).
103. Maor Y, Hagin M, Belausov N et al.: Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J. Infect. Dis. 199(5), 619-624 (2009).
104. Steinkraus G, White R, Friedrich L: Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J. Antimicrob. Chemother. 60(4), 788-794 (2007).
105. Wang G, Hindler JF, Ward KW, Bruckner DA: Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J. Clin. Microbiol. 44(11), 3883-3886 (2006).
106. Sader HS, Fey PD, Fish DN et al.: Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. Antimicrob. Agents Chemother. 53(10), 4127-4132 (2009).
107. Sakoulas G, Moise-Broder PA, Schentag J et al.: Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42(6), 2398-2402 (2004).
108. Soriano A, Marco F, Martinez JA et al.: Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46(2), 193-200 (2008). (Pubitemid 351269157)
109. Rolston KV, Nguyen H, Amos G et al.: A randomized double-blind trial of vancomycin versus teicoplanin for the treatment of Gram-positive bacteremia in patients with cancer. J. Infect. Dis. 169(2), 350-355 (1994).
110. Van der AP, Aoun M, Meunier F: Randomized study of vancomycin versus teicoplanin for the treatment of Gram-positive bacterial infections in immunocompromised hosts. Antimicrob. Agents Chemother. 35(3), 451-457 (1991).
111. Yalaz M, Cetin H, Akisu M et al.: Experience with teicoplanin in the treatment of neonatal staphylococcal sepsis. J. Int. Med. Res. 32(5), 540-548 (2004).
112. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E: The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin. Infect. Dis. 41(Suppl. 5), S354-S367 (2005).
113. Florescu I, Beuran M, Dimov R et al.: Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. J. Antimicrob. Chemother. 62(Suppl. 1), i17-i28 (2008).
114. Sacchidanand S, Penn RL, Embil JM et al.: Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a Phase 3, randomized, double-blind trial. Int. J. Infect. Dis. 9(5), 251-261 (2005).
115. Stein GE, Craig WA: Tigecycline: a critical analysis. Clin. Infect. Dis. 43(4), 518-524 (2006).
116. Gardiner D, Dukart G, Cooper A, Babinchak T: Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 Phase III clinical trials. Clin. Infect. Dis. 50(2), 229-238 (2010).
117. Koomanachai P, Crandon JL, Nicolau DP: Newer developments in the treatment of Gram-positive infections. Expert Opin. Pharmacother. 10(17), 2829-2843 (2009).
118. Jaksic B, Martinelli G, Perez-Oteyza J et al.: Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin. Infect. Dis. 42(5), 597-607 (2006).
119. Lin DF, Zhang YY, Wu JF et al.: Linezolid for the treatment of infections caused by Gram-positive pathogens in China. Int. J. Antimicrob. Agents 32(3), 241-249 (2008).
120. Stevens DL, Herr D, Lampiris H et al.: Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. 34(11), 1481-1490 (2002).
121. Tascini C, Gemignani G, Doria R et al.: Linezolid treatment for Gram-positive infections: a retrospective comparison with teicoplanin. J. Chemother. 21(3), 311-316 (2009).
122. Wilcox M, Nathwani D, Dryden M: Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections. J. Antimicrob. Chemother. 53(2), 335-344 (2004).
123. Falagas ME, Siempos II, Vardakas KZ: Linezolid versus glycopeptide or b-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect. Dis. 8(1), 53-66 (2008).
124. Wilcox MH, Tack KJ, Bouza E et al.: Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a Phase 3 study. Clin. Infect. Dis. 48(2), 203-212 (2009).
125. Jang HC, Kim SH, Kim KH et al.: Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem. Clin. Infect. Dis. 49(3), 395-401 (2009).
126. Gandelman K, Zhu T, Fahmi OA et al.: Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism. J. Clin. Pharmacol. DOI: 10.1177/0091270010366445 (2010) (Epub ahead of print).
127. Falagas ME, Vardakas KZ: Benefit-risk assessment of linezolid for serious Gram-positive bacterial infections. Drug Saf. 31(9), 753-768 (2008).
128. Sanchez GM, de la Torre MA, Morales G et al.: Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 303(22), 2260-2264 (2010).
129. Morales G, Picazo JJ, Baos E et al.: Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin. Infect. Dis. 50(6), 821-825 (2010).
130. Potoski BA, Adams J, Clarke L et al.: Epidemiological profile of linezolid-resistant coagulase-negative staphylococci. Clin. Infect. Dis. 43(2), 165-171 (2006).
131. Tsiodras S, Gold HS, Sakoulas G et al.: Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358(9277), 207-208 (2001).
132. Silverman JA, Perlmutter NG, Shapiro HM: Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother. 47(8), 2538-2544 (2003).
133. Fowler VG Jr, Boucher HW, Corey GR et al.: Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 355(7), 653-665 (2006).
134. Papadopoulos S, Ball AM, Liewer SE et al.: Rhabdomyolysis during therapy with daptomycin. Clin. Infect. Dis. 42(12), e108-e110 (2006).
135. Patel SJ, Samo TC, Suki WN: Early-onset rhabdomyolysis related to daptomycin use. Int. J. Antimicrob. Agents 30(5), 472-474 (2007).
136. Enoch DA, Bygott JM, Daly ML, Karas JA: Daptomycin. J. Infect. 55(3), 205-213 (2007).
137. Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J: Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J. Infect. Dis. 191(12), 2149-2152 (2005).
138. Patel JB, Jevitt LA, Hageman J, McDonald LC, Tenover FC: An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin. Infect. Dis. 42(11), 1652-1653 (2006).
139. Cui L, Tominaga E, Neoh HM, Hiramatsu K: Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50(3), 1079-1082 (2006).
140. Mwangi MM, Wu SW, Zhou Y et al.: Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc. Natl Acad. Sci. USA 104(22), 9451-9456 (2007).
141. Stryjewski ME, Graham DR, Wilson SE et al.: Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by Gram-positive organisms. Clin. Infect. Dis. 46(11), 1683-1693 (2008).
142. Stryjewski ME, Chu VH, O'Riordan WD et al.: Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by Gram-positive bacteria: FAST 2 study. Antimicrob. Agents Chemother. 50(3), 862-867 (2006).
143. Raad I, Darouiche R, Vazquez J et al.: Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens. Clin. Infect. Dis. 40(3), 374-380 (2005).
144. Dowell JA, Goldstein BP, Buckwalter M, Stogniew M, Damle B: Pharmacokinetic- pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic. J. Clin. Pharmacol. 48(9), 1063-1068 (2008).
145. Barton E, MacGowan A: Future treatment options for Gram-positive infections - looking ahead. Clin. Microbiol. Infect. 15(Suppl. 6), 17-25 (2009).
146. Stryjewski ME, Corey GR: New treatments for methicillin-resistant Staphylococcus aureus. Curr. Opin. Crit. Care 15(5), 403-412 (2009).
147. Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS: A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin. Infect. Dis. 46(5), 647-655 (2008).
148. Talbot GH, Thye D, Das A, Ge Y: Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob. Agents Chemother. 51(10), 3612-3616 (2007).